{
    "2021-06-04": [
        [
            {
                "time": "2023-11-01",
                "original_text": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Stock Sinks",
                        "Market Gains"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers",
                "features": {
                    "keywords": [
                        "Merus",
                        "New Data",
                        "Zeno Program",
                        "NRG1 Fusion Cancers"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Clinical Data",
                        "Verzenio",
                        "Oral SERD Programs",
                        "ASCO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}